Pulmatrix (PULM) Announces $6.75M Direct Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Pulmatrix Announces $6.75 Million Registered Direct Offering
December 15, 2021 8:00 AM ESTLEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ --Â Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of an aggregate of 6,745 shares of convertible preferred stock and warrants to purchase up to an aggregate of 5,620,834 shares of common stock for gross proceeds of $6.75 million in a registered direct offering. The shares of... More
